This collaborative approach supports both clinical outcomes and treatment satisfaction
Conclusions OSA is one of the most common and serious sleep-related breathing disorders, which affects cardiovascular morbidity and mortality, as well as the quality of life [1, 3, 110]
While these symptoms can catch you off guard, they are typically mild to moderate and tend to fade within a few weeks as the body adjusts to the medication
Novo Nordisk is seeking a court order on an expedited basis to ensure people can access the accurate, complete picture of the treatments available to them today, it said
Slight changes to the Highmark process this round are the following: Fully insured and ASO clients that would like Highmark to submit data to CMS on their behalf must submit all required information via the Prescription Drug Data Collection (RxDC) Survey below by no later than May 1, 2024
Pulmonary aspiration The American Society of Anesthesiologists (ASA) issued a press release about concerns over Ozempic and other GLP-1 RAs in June 2023